Skip to content
OpenCapital
Get started

Capricor Therapeutics CAPR Q3 2025 earnings

Reported November 10, 2025 · After market close

Revenue-Miss by $600.0KDiluted EPS-$0.54In line
Revenue estimate$600.0K
EPS estimate-$0.54

Next report

Aug 11, 2026 (In 4 weeks)
Revenue estimate$2.1M
EPS estimate-$0.58

Financials

Q3 2025

Income statement

See full
Revenue--100%
Operating income-$26.3M-102%
Net income-$24.6M-95.7%
EPS (diluted)-$0.54-42.1%

Balance sheet

See full
Cash & equivalents$19.5M-71.5%
Total debt$14.5M+189%
Total equity$83.9M+22.9%
Total assets$126.4M+36.0%

Cash flow

See full
Operating cash flow-$19.7M-69.1%
CapEx$55.8K+511%
Free cash flow-$19.7M-69.5%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$329.62M-38.7%
Enterprise value$324.65M-31.5%
P/S29.6×+6.5×

Profitability

See full
Operating margin-778.8%-1,038pp
Net margin-736.6%-981pp
FCF margin-563.9%-954pp

Returns & leverage

See full
Return on equity-107.8%—
Debt / equity0.2×+0.1×
Current ratio3.6×-0.6×

Versus estimates

Revenue

Q4 2024$11.1MBeat by $5.6M

Diluted EPS

Q1 2026-$0.59Miss by $0.04Q4 2025-$0.62Miss by $0.11
Q3 2025-$0.54In line
Q2 2025-$0.57Miss by $0.09Q1 2025-$0.53Miss by $0.20Q4 2024-$0.16Beat by $0.15

Ask the moment Capricor Therapeutics reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Capricor Therapeutics report Q3 2025 earnings?
Capricor Therapeutics (CAPR) reported Q3 2025 earnings on November 10, 2025 after market close.
What were Capricor Therapeutics's Q3 2025 revenue and EPS?
Capricor Therapeutics reported revenue of - and diluted EPS of $-0.54 for Q3 2025.
Did Capricor Therapeutics beat estimates in Q3 2025?
Revenue missed the consensus estimate of $600.0K by $600.0K. EPS beat the consensus estimate of $-0.54 by $0.00.
How did Capricor Therapeutics's Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 100.0% from $2.3M a year earlier and diluted EPS declined 42.1% from $-0.38.
Where can I find Capricor Therapeutics's Q3 2025 SEC filings?
You can read the 8-K earnings release (0001104659-25-109119) and the 10-Q periodic report (0001104659-25-109298) directly on SEC EDGAR. The filing index links above go to sec.gov.